EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-world benchmarks for metastatic urothelial carcinoma: a single-center analysis of two standard immunotherapy pathways in Romania

Daniel-Vasile Dulf, Anamaria Larisa Burnar, Doina-Ramona Matei, Patricia-Lorena Dulf, Raluca Maria Hendea, Cătălina Bungărdean, Andreea Hopârtean, Dinu Bolunduţ, Iulia Andras, Maximilian Buzoianu, Nicoale Crişan, Tudor-Eliade Ciuleanu und 1 weitere

Medicine and Pharmacy Reports · 30.03.2026

DOI: 10.15386/mpr-2925 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicine and Pharmacy Reports, online erschienen am 30.03.2026. Verfasst von Daniel-Vasile Dulf und 12 weiteren Autor:innen. Beteiligte Einrichtung: 10th Department - Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To establish a real-world benchmark for treatment with the immune checkpoint inhibitors (ICI) and clinical outcomes for patients with metastatic urothelial carcinoma (mUC) by analyzing two distinct, standard-of-care therapeutic sequences at a single Romanian tertiary care center.

Methods

We conducted a retrospective analysis of 30 patients with mUC treated between January 1, 2020, and April 30, 2025. Patients were analyzed in two clinically distinct cohorts: the Avelumab Maintenance Cohort (N=12), which included platinum-eligible patients who responded to first-line platinum-based chemotherapy (PBC) followed by avelumab maintenance, and the Pembrolizumab Cohort (N=18), consisting of patients who received pembrolizumab therapy following disease progression after PBC. The primary endpoint was time to treatment failure (TTF). Secondary endpoints included overall survival (OS) and the incidence of grade ≥3 treatment-related adverse events (TRAEs).

Results

The two cohorts displayed different baseline characteristics and clinical trajectories. The Avelumab Maintenance cohort, selected for chemotherapy-sensitive disease, demonstrated a higher disease control rate (DCR) of 91.7%. The Pembrolizumab cohort, representing a more clinically diverse and challenging population, had a DCR of 55.6%. In the Avelumab cohort, median TTF and median OS were not reached. In the Pembrolizumab cohort, the median TTF was 10.2 months and median OS was 21.8 months. Grade ≥3 TRAEs were infrequent, occurring in 1 of 12 patients (8.3%) in the Avelumab cohort and 2 of 18 patients (11.1%) in the Pembrolizumab cohort, with no new safety signals identified.

Conclusion

This single-center study provides a context-specific presentation of mUC treated with ICIs effectiveness and safety in the Romanian healthcare context and highlights the impact of systemic factors, such as national healthcare reimbursement policies, on clinical practice.

Schlagwörter

Stichwörter der Autor:innen

Romaniaavelumabimmune checkpoint inhibitorspembrolizumaburinary bladder neoplasms

Autor:innen und Institutionen

  • 10th Department - Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Clinical Municipal Hospital Cluj-Napoca, Cluj-Napoca, Romania.
  • "Prof. Dr. Ion Chiricuţă" Institute of Oncology, Cluj-Napoca, Romania.
  • "Prof. Dr. Nicolae Stăncioiu" Heart Institute, Cluj-Napoca, Romania.
  • Department of Pathology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Department of Urology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Zitieren

APA

Dulf, D. V., Burnar, A. L., Matei, D. R., Dulf, P. L., Hendea, R. M., Bungărdean, C., Hopârtean, A., Bolunduţ, D., Andras, I., Buzoianu, M., Crişan, N., Ciuleanu, T. E., & Coadă, C. A. (2026). Real-world benchmarks for metastatic urothelial carcinoma: a single-center analysis of two standard immunotherapy pathways in Romania. Medicine and Pharmacy Reports. https://doi.org/10.15386/mpr-2925

Vancouver

Dulf DV, Burnar AL, Matei DR, Dulf PL, Hendea RM, Bungărdean C, et al. Real-world benchmarks for metastatic urothelial carcinoma: a single-center analysis of two standard immunotherapy pathways in Romania. Medicine and Pharmacy Reports. 2026. doi:10.15386/mpr-2925

BibTeX
@article{Dulf2026,
  author = {Dulf, Daniel-Vasile and Burnar, Anamaria Larisa and Matei, Doina-Ramona and Dulf, Patricia-Lorena and Hendea, Raluca Maria and Bungărdean, Cătălina and Hopârtean, Andreea and Bolunduţ, Dinu and Andras, Iulia and Buzoianu, Maximilian and Crişan, Nicoale and Ciuleanu, Tudor-Eliade and Coadă, Camelia Alexandra},
  title = {Real-world benchmarks for metastatic urothelial carcinoma: a single-center analysis of two standard immunotherapy pathways in Romania},
  journal = {Medicine and Pharmacy Reports},
  year = {2026},
  doi = {10.15386/mpr-2925}
}
Kostenlos starten →